Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.
1. A method comprising:
receiving a non-frozen stool or portion thereof from a human donor, wherein the stool or portion thereof comprises fecal bacteria, and wherein the donor has been screened for infectious agents;
homogenizing the stool or portion thereof in a diluent comprising a cryoprotectant; and
encapsulating the fecal bacteria and cryoprotectant in a capsule;
wherein the fecal bacteria are not cultured.
2. The method of claim 1 , further comprising lyophilizing the fecal bacteria and cryoprotectant prior to encapsulating.
3. The method of claim 1 , further comprising filtering the fecal bacteria and diluent prior to encapsulating.
4. The method of claim 1 , further comprising testing the stool or portion thereof for pathogens.
5. The method of claim 1 , wherein the cryoprotectant comprises glycerol.
6. The method of claim 1 , wherein the cryoprotectant comprises trehalose.
7. The method of claim 1 , wherein the diluent further comprises an antioxidant.
8. The method of claim 7 , wherein the antioxidant comprises cysteine.
9. The method of claim 1 , wherein the capsule comprises an enteric coating.
10. The method of claim 1 , wherein the fecal bacteria comprise a bacterial strain from the phylum Firmicutes or the genus Bacteroides.
11. The method of claim 1 , further comprising selectively removing strains of bacteria from the fecal bacteria prior to the encapsulating.
12. The method of claim 1 , wherein the fecal bacteria are not lyophilized.
13. A method of manufacturing a capsule comprising a population of fecal bacteria for administering to a subject in need thereof, the method comprising:
receiving a non-frozen stool or portion thereof from a human donor, wherein the stool or portion thereof comprises the population of fecal bacteria;
testing the stool or portion thereof for pathogens;
homogenizing the stool or portion thereof in a diluent comprising a cryoprotectant;
lyophilizing the population of fecal bacteria and the cryoprotectant to produce a lyophilizate; and
encapsulating the lyophilizate in the capsule;
wherein the population of fecal bacteria is not cultured.
14. The method of claim 13 , further comprising filtering the population of fecal bacteria prior to lyophilizing.
15. The method of claim 14 , wherein the fecal bacteria are free of rough particulate matter after the filtering.
16. The method of claim 13 , wherein the cryoprotectant comprises trehalose.
17. The method of claim 13 , wherein the stool or portion thereof is received in a stool collection device.
18. The method of claim 13 , wherein the capsule comprises an enteric coating.
19. The method of claim 13 , wherein the diluent further comprises an antioxidant.
20. The method of claim 19 , wherein the antioxidant comprises cysteine.
21. The method of claim 13 , wherein the capsule is administered to the subject in need thereof to treat a disorder selected from the group consisting of: a Clostridium difficile ( C. difficile ) infection, irritable bowel syndrome, inflammatory bowel disease, ulcerative colitis and Crohn's disease.